A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 307 participants.

Also called NCT01760460

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 307 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01760460
Main results
  • Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia Atherosclerosis, 2017-06 DOI, PubMed 28478132

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01760460. Randomized; double masking; primary purpose treatment. Start 2013-03-14 (actual); primary completion 2015-03-04 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)
Condition
Dyslipidemia
Intervention (Drug)
Anacetrapib
Intervention (Drug)
Placebo for anacetrapib
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct01760460
Content hash
95a3e50a4c4f770b258cd6d43366a4f3171a32b613a9acee3040ebb35a047653